NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.0b

Last Updated

2021/05/15 22:27 UTC

Data Sources

Company Financials +

Executive Summary

Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. More Details


Snowflake Analysis

Excellent balance sheet with moderate growth potential.

Share Price & News

How has Nano-X Imaging's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NNOX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: NNOX's weekly volatility has decreased from 22% to 15% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-24.7%

NNOX

-2.6%

US Medical Equipment

-1.9%

US Market


1 Year Return

n/a

NNOX

34.2%

US Medical Equipment

50.5%

US Market

Return vs Industry: Insufficient data to determine how NNOX performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how NNOX performed against the US Market.


Shareholder returns

NNOXIndustryMarket
7 Day-24.7%-2.6%-1.9%
30 Day-35.9%-1.3%-0.6%
90 Day-66.9%-3.3%0.1%
1 Yearn/a35.3%34.2%53.0%50.5%
3 Yearn/a67.8%63.8%61.1%51.0%
5 Yearn/a151.1%132.7%125.7%100.6%

Long-Term Price Volatility Vs. Market

How volatile is Nano-X Imaging's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nano-X Imaging undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NNOX ($21.91) is trading below our estimate of fair value ($319.3)

Significantly Below Fair Value: NNOX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NNOX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: NNOX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NNOX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NNOX is overvalued based on its PB Ratio (4.6x) compared to the US Medical Equipment industry average (4.4x).


Future Growth

How is Nano-X Imaging forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

71.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NNOX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: NNOX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NNOX's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if NNOX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if NNOX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NNOX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Nano-X Imaging performed over the past 5 years?

-68.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: NNOX is currently unprofitable.

Growing Profit Margin: NNOX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NNOX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare NNOX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NNOX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.1%).


Return on Equity

High ROE: NNOX has a negative Return on Equity (-21.8%), as it is currently unprofitable.


Financial Health

How is Nano-X Imaging's financial position?


Financial Position Analysis

Short Term Liabilities: NNOX's short term assets ($222.2M) exceed its short term liabilities ($18.3M).

Long Term Liabilities: NNOX's short term assets ($222.2M) exceed its long term liabilities ($992.0K).


Debt to Equity History and Analysis

Debt Level: NNOX is debt free.

Reducing Debt: NNOX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NNOX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NNOX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Nano-X Imaging current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NNOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NNOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NNOX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NNOX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NNOX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Ran Poliakine (52 yo)

1.67yrs

Tenure

Mr. Ran Poliakine has been Chairman of Nano-X Imaging Ltd. since August 21, 2020 and has been its Chief Executive Officer since September 2019. He is the Founder of Wellsense USA, Inc. and Wellsense Ltd. H...


Leadership Team

Experienced Management: NNOX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: NNOX's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: NNOX only recently listed within the past 12 months.


Top Shareholders

Company Information

Nano-X Imaging Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nano-X Imaging Ltd.
  • Ticker: NNOX
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.043b
  • Shares outstanding: 47.60m
  • Website: https://www.nanox.vision

Number of Employees


Location

  • Nano-X Imaging Ltd.
  • Communications Center
  • Neve Ilan
  • 9085000
  • Israel

Listings


Biography

Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. Its X-ray source is based on a novel dig...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 22:27
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.